Epigenic Therapeutics
Company Type: Therapeutic development
Main focus: Developing novel treatments through regulation of the epigenome
Company stage: Pre-clinical
Diseases: Metabolic/liver disease, ophthalmology disorders, central nervous system disorders, cancer
Genome-editing tool: EPIREG® optimised CRISPR-Cas
Funding stage: Series A
Location: Basheng Road, Shanghai, China
Website: https://www.epigenictx.com/
Pipeline: https://www.epigenictx.com/innovation/pipeline
Partners:
Epigenic Therapeutics is a biotech company focused on epigenome-based therapies. Its proprietary EPIREG® platform harnesses advanced CRISPR-Cas systems to regulate gene expression without altering DNA sequences, a technique that aims to address various diseases including metabolic disorders, cancer and chronic viral infections. Using a lipid nanoparticle-based delivery system, Epigenic Therapeutics aims to develop novel treatments with precise targeting, and has shown promising results in pre-clinical models, e.g., in chronic hepatitis B virus (HBV).